DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AMRUTAJAN HEALTH LTD (AMRUTANJAN) share price today?

AMRUTAJAN HEALTH LTD (AMRUTANJAN) is trading at ₹538.2 on the NSE, up 0.66% on the day. Source: DocStoX.

What is the PE ratio of AMRUTAJAN HEALTH LTD?

AMRUTAJAN HEALTH LTD has a price-to-earnings (PE) ratio of 30.6 in the Healthcare sector.

What is the market capitalisation of AMRUTAJAN HEALTH LTD?

AMRUTAJAN HEALTH LTD has a market capitalisation of approximately ₹1,561 crore.

AMRUTAJAN HEALTH LTD

AMRUTANJAN·NSE·Healthcare

₹538.20▲ +3.55 (+0.66%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹531.00

₹538.70

52W₹486

₹79117%

Open

₹536.70

High

₹538.70

Low

₹531.00

Prev Close

₹534.65

Volume

17.0K

VWAP

₹534.64

Snapshot

Key fundamentals

Market Cap

₹1,561 Cr

P/E Ratio

30.61Fair

P/B Ratio

4.18

EPS

₹17.58

Book Value

₹128.06

ROE

18.92%Strong

ROCE

22.00%Efficient

Dividend Yield

0.37%

Debt / Equity

0.01Low

Face Value

₹1.00

52W High

₹790.95

52W Low

₹486.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹187

▼ 65.3%downside

Trading at ₹538 — 65% above our estimate

BearFair valueBull

₹159₹187₹225

/100

Business quality — Watch the fundamentals

Growth 0Profitability 61Efficiency 43Valuation 74

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹128 book

₹176

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹225

Analyst target

No analyst coverage

—

Blended fair value₹187

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

30.6Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

18.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,561 Cr

P/B

4.18

EPS

₹17.58

Div Yield

0.37%

What changed

Recent changes

Foreign investors+0.3% stake last quarter
Domestic institutions-0.4% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 30.6×

Growth

Steady

+10% rev CAGR

Profitability

Excellent

18.9% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %62.8%

Turnover₹90.80L Cr

Trades1,145

VWAP₹534.64

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.8%

+8.6%

10Y

+11.2%

Profit

+13.1%

-1.0%

10Y

+10.2%

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 26.7%
Company's working capital requirements have reduced from 123 days to 96.0 days

Watch-outs

Cons

The company has delivered a poor sales growth of 8.59% over past five years.
Promoter holding has decreased over last 3 years: -3.52%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.27 pts; domestic institutions reduced 0.37 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

47%

Promoter

Promoters

46.5%0.00

Public

38.7%+0.11

FII / FPI

2.4%+0.27

DII

12.3%-0.37

Quarterly trend

Ownership over time

Q1 FY27

Promoter46.52%

FII2.44%

DII12.29%

Public38.72%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions